Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 6;10(1):86. doi: 10.3390/vaccines10010086

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Neutralization activities against wild-type and SARS-CoV-2 variants measured by surrogate virus neutralization test (sVNT). The serum samples obtained from participants who received two completed doses of the inactivated vaccine, CoronaVac; followed by the inactivated vaccine, BBIBP (green); the viral vector vaccine, AZD1222 (red); or the mRNA vaccine, BNT162b2 (blue), at 3–4 months after the first dose were compared. The neutralizing activities against SARS-CoV-2 Wide-type (A), Alpha (B.1.1.7) (B), Beta (B.1.351) (C), and Delta (B.1.617.2) (D) were shown. Lines represent medians with interquartile ranges (IQR); ns indicates no significant difference; p-value < 0.001 (***), 0.0001 (****).